IVAN D HORAK Insider Trading $ENZN ENZON PHARMACEUTICALS, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for IVAN D HORAK.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of IVAN D HORAK. IVAN D HORAK is EVP, President of R&D and CSO in ENZON PHARMACEUTICALS, INC. ($ENZN) and EVP, R&D, Chief Sci. Officer in ENZON PHARMACEUTICALS, INC. ($ENZN) and EVP, R&D, Chief Scientific Off in ENZON PHARMACEUTICALS, INC. ($ENZN) and EVP, R&D, CSO in ENZON PHARMACEUTICALS, INC. ($ENZN) and EVP,R&D, CSO in ENZON PHARMACEUTICALS, INC. ($ENZN) and EVP-R&D & Chief Scien. Officer in ENZON PHARMACEUTICALS, INC. ($ENZN) and President of R&D in ENZON PHARMACEUTICALS, INC. ($ENZN).
IVAN D HORAK in ENZON PHARMACEUTICALS, INC.
Trading Symbol: ENZNIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of IVAN D HORAK: EVP, President of R&D and CSO, President of R&D, EVP, R&D, CSO, EVP,R&D, CSO, EVP, R&D, Chief Sci. Officer, EVP, R&D, Chief Scientific Off, EVP-R&D & Chief Scien. Officer
Holdings: 121,376 shares
Current Value: $42,482
Latest Transaction: Apr 01 2011
$ENZN Market Capitalization: $15.28M
$ENZN Previous Close: $0.35
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of IVAN D HORAK in ENZON PHARMACEUTICALS, INC.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 01 2011 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Payment of Exercise | F | 10.76 | 886 | 9,533 | 121,376 | 122.3 K to 121.4 K (-0.72 %) |
Apr 01 2011 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | J | 0.00 | 2,500 | 0 | 122,262 | 119.8 K to 122.3 K (+2.09 %) |
Nov 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 0.00 | 3,000 | 0 | 0 | |
Nov 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Payment of Exercise | F | 10.92 | 1,063 | 11,608 | 137,125 | 138.2 K to 137.1 K (-0.77 %) |
Nov 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 0.00 | 3,000 | 0 | 138,188 | 135.2 K to 138.2 K (+2.22 %) |
Sep 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, President of R ... | Grant | A | 0.00 | 15,000 | 0 | 135,188 | 120.2 K to 135.2 K (+12.48 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 7.40 | 79,200 | 586,080 | 66,500 | |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 7.14 | 162,800 | 1,162,392 | 0 | |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 7.14 | 2,000 | 14,280 | 162,800 | |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 7.14 | 35,200 | 251,328 | 164,800 | |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 6.97 | 35,000 | 243,950 | 0 | |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 10.63 | 200,000 | 2,126,660 | 120,188 | 320.2 K to 120.2 K (-62.46 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 7.40 | 79,200 | 586,080 | 320,188 | 241 K to 320.2 K (+32.86 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 7.14 | 162,800 | 1,162,392 | 240,988 | 78.2 K to 241 K (+208.22 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 10.67 | 1,700 | 18,132 | 78,188 | 79.9 K to 78.2 K (-2.13 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 7.14 | 2,000 | 14,280 | 79,888 | 77.9 K to 79.9 K (+2.57 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 10.81 | 57,200 | 618,200 | 77,888 | 135.1 K to 77.9 K (-42.34 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 7.14 | 35,200 | 251,328 | 135,088 | 99.9 K to 135.1 K (+35.24 %) |
Sep 17 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 6.97 | 35,000 | 243,950 | 99,888 | 64.9 K to 99.9 K (+53.94 %) |
Sep 07 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Option Exercise | M | 0.00 | 20,000 | 0 | 0 | |
Sep 07 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Payment of Exercise | F | 10.58 | 7,084 | 74,949 | 64,888 | 72 K to 64.9 K (-9.84 %) |
Sep 07 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Buy | M | 0.00 | 20,000 | 0 | 71,972 | 52 K to 72 K (+38.48 %) |
Apr 13 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | President of R&D | Option Exercise | M | 0.00 | 19,860 | 0 | 26,480 | |
Apr 13 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | President of R&D | Payment of Exercise | F | 10.48 | 7,035 | 73,727 | 51,972 | 59 K to 52 K (-11.92 %) |
Apr 13 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | President of R&D | Buy | M | 0.00 | 19,860 | 0 | 59,007 | 39.1 K to 59 K (+50.73 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.30 | 85,903 | 798,898 | 39,147 | 125.1 K to 39.1 K (-68.69 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.30 | 8,720 | 81,133 | 125,050 | 133.8 K to 125.1 K (-6.52 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.31 | 100 | 931 | 133,770 | 133.9 K to 133.8 K (-0.07 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.32 | 1,600 | 14,912 | 133,870 | 135.5 K to 133.9 K (-1.18 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.32 | 300 | 2,796 | 135,470 | 135.8 K to 135.5 K (-0.22 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.33 | 4,406 | 41,108 | 135,770 | 140.2 K to 135.8 K (-3.14 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.33 | 100 | 933 | 140,176 | 140.3 K to 140.2 K (-0.07 %) |
Feb 24 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, CSO | Sell | S | 9.34 | 200 | 1,867 | 140,276 | 140.5 K to 140.3 K (-0.14 %) |
Jan 29 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP,R&D, CSO | Grant | A | 0.00 | 16,465 | 0 | 140,476 | 124 K to 140.5 K (+13.28 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Payment of Exercise | F | 10.91 | 10,053 | 109,678 | 124,011 | 134.1 K to 124 K (-7.50 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | J | 0.00 | 8,333 | 0 | 134,064 | 125.7 K to 134.1 K (+6.63 %) |
Jan 20 2010 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | J | 0.00 | 18,333 | 0 | 134,064 | 115.7 K to 134.1 K (+15.84 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 2,250 | 0 | 3,000 | |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Payment of Exercise | F | 10.37 | 797 | 8,265 | 134,064 | 134.9 K to 134.1 K (-0.59 %) |
Nov 25 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 2,250 | 0 | 134,861 | 132.6 K to 134.9 K (+1.70 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 19,860 | 0 | 46,340 | |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Sell | S | 6.12 | 7,035 | 43,054 | 122,924 | 130 K to 122.9 K (-5.41 %) |
Apr 07 2009 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 19,860 | 0 | 128,977 | 109.1 K to 129 K (+18.20 %) |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Option Exercise | M | 0.00 | 2,250 | 0 | 5,250 | |
Nov 25 2008 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP, R&D, Chief Sci ... | Buy | M | 0.00 | 2,250 | 0 | 108,250 | 106 K to 108.3 K (+2.12 %) |
May 19 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 7.40 | 145,700 | 1,078,180 | 145,700 | |
Apr 05 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 8.04 | 66,200 | 532,248 | 66,200 | |
Apr 05 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 8.04 | 122,900 | 988,116 | 122,900 | |
Mar 07 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Buy | P | 6.87 | 200 | 1,374 | 8,500 | 8.3 K to 8.5 K (+2.41 %) |
Mar 07 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Buy | P | 6.88 | 1,300 | 8,939 | 8,300 | 7 K to 8.3 K (+18.57 %) |
Mar 07 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Buy | P | 6.87 | 500 | 3,434 | 7,000 | 6.5 K to 7 K (+7.69 %) |
Mar 07 2006 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Buy | P | 6.86 | 1,000 | 6,858 | 6,500 | 5.5 K to 6.5 K (+18.18 %) |
Nov 28 2005 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 0.00 | 7,500 | 0 | 7,500 | |
Nov 28 2005 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 6.97 | 35,000 | 243,950 | 35,000 | |
Oct 05 2005 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Buy | P | 7.18 | 5,500 | 39,490 | 5,500 | 0 to 5.5 K |
Sep 07 2005 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 0.00 | 50,000 | 0 | 50,000 | |
Sep 07 2005 | ENZN | ENZON PHARMACEUTIC ... | HORAK IVAN D | EVP-R&D & Chief Sci ... | Option Exercise | A | 7.14 | 200,000 | 1,428,000 | 200,000 |
Page: 1